US-based vaccine company Novavax has chosen its lead vaccine candidate for Covid-19, NVX-CoV2373. The company now plans to initiate its first in-human trial in mid-May; results of this combined Phase I/II study of 130 individuals are expected in July.

NVX-CoV2373 was created using Novavax’s proprietary nanoparticle technology and incorporates the company’s Matrix-M adjuvant, which enhances immune responses.

Novavax has been working on animal studies of several Covid-19 vaccine candidates with the support of University of Maryland School of Medicine associate professor Dr. Matthew Frieman and funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Novavax CEO and president Stanley C. Erck noted: “Because of the tireless efforts and commitment of the Novavax team and our collaborators, we are preparing to initiate the NVX-CoV2373…trial in mid-May, weeks ahead of schedule.

“This progress demonstrates the ability of our recombinant nanoparticle technology to rapidly create vaccine candidates for emerging viruses like SARS-CoV-2 [, which causes Covid-19].

In addition, the performance of NVX-CoV2373 in multiple preclinical studies and testing gives us increased confidence in its potential to protect against Covid-19 disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.